Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-01

FDA Approved: DALFAMPRIDINE — Supplemental Application (Ascend Laboratories, LLC)

View source ↗

Summary

The FDA approved a supplemental application for a generic dalfampridine product from Ascend Laboratories, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalfampridine (dalfampridine)

Snippet

SUPPL AP for DALFAMPRIDINE (DALFAMPRIDINE)